Vigil Neuroscience, Inc. VIGL
We take great care to ensure that the data presented and summarized in this overview for Vigil Neuroscience, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VIGL
View all-
Atlas Venture Life Science Advisors, LLC5.84MShares$14.8 Million1.62% of portfolio
-
Northpond Ventures, LLC4.21MShares$10.7 Million51.65% of portfolio
-
Siren, L.L.C. New York, NY1.99MShares$5.06 Million0.15% of portfolio
-
Bvf Inc San Francisco, CA1.81MShares$4.61 Million0.11% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.51MShares$3.83 Million0.0% of portfolio
-
Sphera Funds Management Ltd. Tel Aviv, L31.5MShares$3.82 Million0.52% of portfolio
-
683 Capital Management, LLC New York, NY1.4MShares$3.56 Million0.17% of portfolio
-
Vanguard Group Inc Valley Forge, PA975KShares$2.48 Million0.0% of portfolio
-
Ensign Peak Advisors, Inc Salt Lake City, UT703KShares$1.79 Million0.0% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA561KShares$1.42 Million0.87% of portfolio
Latest Institutional Activity in VIGL
Top Purchases
Top Sells
About VIGL
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at VIGL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 19
2024
|
Ivana Magovcevic Liebisch President and CEO |
BUY
Open market or private purchase
|
Direct |
5,000
+2.2%
|
$5,000
$1.68 P/Share
|
|
Dec 19
2024
|
Haeberlein Samantha L. Budd |
BUY
Open market or private purchase
|
Direct |
12,000
+50.0%
|
$12,000
$1.71 P/Share
|
|
Dec 18
2024
|
Ivana Magovcevic Liebisch President and CEO |
BUY
Open market or private purchase
|
Direct |
5,000
+2.25%
|
$5,000
$1.67 P/Share
|
|
Dec 05
2024
|
Ivana Magovcevic Liebisch President and CEO |
BUY
Open market or private purchase
|
Direct |
5,000
+2.3%
|
$10,000
$2.34 P/Share
|
|
Nov 20
2023
|
Ivana Magovcevic Liebisch President and CEO |
BUY
Open market or private purchase
|
Direct |
4,000
+1.89%
|
$12,000
$3.75 P/Share
|
|
Nov 18
2022
|
Spyridon Papapetropoulos Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
300
-6.98%
|
$4,200
$14.0 P/Share
|
|
Nov 18
2022
|
Spyridon Papapetropoulos Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
300
+6.52%
|
$300
$1.89 P/Share
|
|
May 17
2022
|
Clay Thorp Director |
BUY
Open market or private purchase
|
Indirect |
14,893
+0.95%
|
$29,786
$2.97 P/Share
|
|
May 16
2022
|
Clay Thorp Director |
BUY
Open market or private purchase
|
Indirect |
21,802
+1.39%
|
$43,604
$2.76 P/Share
|
|
May 05
2022
|
Evan Thackaberry SVP, Head of Early Development |
BUY
Open market or private purchase
|
Direct |
1,500
+50.0%
|
$6,000
$4.0 P/Share
|
|
May 03
2022
|
Spyridon Papapetropoulos Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
4,000
+50.0%
|
$12,000
$3.4 P/Share
|
|
May 03
2022
|
Jennifer Lynn Ziolkowski Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
4,000
+50.0%
|
$12,000
$3.77 P/Share
|
|
May 03
2022
|
Christopher Verni General Counsel |
BUY
Open market or private purchase
|
Direct |
4,000
+50.0%
|
$12,000
$3.77 P/Share
|
|
May 03
2022
|
Ivana Magovcevic Liebisch President and CEO |
BUY
Open market or private purchase
|
Direct |
1,000
+0.49%
|
$3,000
$3.94 P/Share
|
|
May 02
2022
|
Ivana Magovcevic Liebisch President and CEO |
BUY
Open market or private purchase
|
Direct |
4,000
+1.94%
|
$12,000
$3.61 P/Share
|
|
Mar 28
2022
|
Clay Thorp Director |
BUY
Open market or private purchase
|
Direct |
3,000
+50.0%
|
$21,000
$7.2 P/Share
|
|
Jan 11
2022
|
Cormorant Asset Management, LP |
BUY
Conversion of derivative security
|
Indirect |
616,786
+50.0%
|
-
|
|
Jan 11
2022
|
Alexandria Venture Investments, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
192,973
+50.0%
|
-
|
|
Jan 11
2022
|
Northpond Ventures Gp, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
355,000
+20.43%
|
$4,970,000
$14.0 P/Share
|
|
Jan 11
2022
|
Northpond Ventures Gp, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,859,498
+50.0%
|
-
|
Last 12 Months Summary
| Open market or private purchase | 27K shares |
|---|